fda warning letter hims & hers compounded semaglutide september 2025 Takes Aim at Hers, Weight-Loss Drugs in New Advertising Blitz FDA issued 25 warning Hims & Hers' Compounded Wegovy

Part of a Bigger Picture Peptide therapy works even better alongside IV therapy, hormone optimization, or nutrition support

Raw reads of sequencing were processed into clean reads by filtering low quality reads

B12 injections are not a weight loss treatment on their own and do not directly cause fat loss

The main metabolites include -caryophyllene, -muscene, methyl butyrate, ethyl butyrate, and citral

Novo Nordisk subsequently extended the semaglutide franchise with Wegovy HD 7.2 mg (FDA-approved 2026), which achieved approximately 19% mean weight loss at 72 weeks in STEP UP and closed much of the efficacy gap with tirzepatide